News

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. In a significant development, ...
Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and ...
The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...
With Bristol Myers Squibb’s long-standing expertise in developing and commercializing medicines on a global scale and legacy in neuroscience, KarXT and the other assets in our pipeline will be ...
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird ...
Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both ...
Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.
Bristol Myers Squibb BMY -1.9% (NYSE: BMY) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is undervalued, as ...
Bristol-Myers Squibb’s P/E Multiple of 11.8x on average consensus EPS of 4.28 for 2019, is lower than 13.0x for Pfizer, 17.3x for Merck, and 15.3x for J&J.